Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells

Blood

Volumn 87, Issue 11, 1996, Pages 4510-4519

  Sporeno, Elisabetta ^b   Savino, Rocco ^b   Ciapponi, Laura ^b   Paonessa, Giacomo ^b   Cabibbo, Andrea ^b   Lahm, Armin ^b   Pulkki, Kari ^b   Sun, Ren Xiao ^b   Toniatti, Carlo ^b   Klein, Bernard ^b   Ciliberto, G ^a  

^a IRBM   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SANT 7; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 9344259121     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.11.4510.bloodjournal87114510     Document Type: Article

References (58)

1. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp130. Blood 86:1243, 1995
2. Kopf M, Lamers M, Bluethman H, Kohler G: IL-6 deficient mice show immunologic abnormalities. Nature 376:339, 1994
3. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561, 1994
4. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54:1, 1993
5. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86:685, 1995
6. Nachbaur DM, Herold M, Maneschg A: Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters. Ann Hematol 62:54, 1991
7. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H: Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77:2794, 1991
8. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 85:765, 1995
9. Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood 85:863, 1995
10. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL6 for human MMs. Nature 332:83, 1988
11. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan R: Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 77:587, 1991
12. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
13. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712, 1993
14. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517, 1989
15. Zhang XG, Bataille R, Wijdenes J, Klein B: Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 69:1373, 1992
16. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 89:232, 1992
17. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S: Interleukin-6 is essential for in vivo development of B lineage neoplasms. J Exp Med 182:243, 1995
18. Huang Y-W, Vitetta ES: Immunotherapy of multiple myeloma. Stem Cells 13:123, 1995
19. Klein B, Wijdnes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R: Murine anti-IL-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198, 1991
20. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
21. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602, 1994
22. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M, Boue F, Galanaud P. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 84:2472, 1994
23. Lu ZY, Brailly J, Wijdenes J, Bataille R, Rossi J-F, Klein B: Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments. Blood 86:3123, 1995
24. Bazan JF: Haemopoietic receptors and helical cytokines. Immunol Today 11:350, 1990
25. Savino R, Lahm A, Salvati AL, Ciapponi L, Sporeno E, Altamura S, Paonessa G, Toniatti C, Ciliberto G: Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J 13:1357, 1994
26. Ehlers M, Grotzinger J, DeHon FD, Mullberg J, Brakenhoff JPJ, Liu J, Wollmer A, Rose-John S: Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol 153:1744, 1994
27. Kishimoto T, Taga T, Akira S: Cytokine signal transduction. Cell 76:253, 1994
28. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz R, Simpson RJ: High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 269:23286, 1994
29. Paonessa G, Graziani R, De Serio A, Savino R, Ciapponi L, Lahm A, Salvati AL, Toniatti C, Ciliberto G: Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling. EMBO J 14:1942, 1995
30. Wells JA: Structural and functional basis for hormone binding and receptor oligomerization. Curr Opin Cell Biol 6:163, 1994
31. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 80:587, 1995
32. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S, Ciliberto C: Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 13:5863, 1994
33. Ciapponi L, Graziani R, Paonessa G, Lahm A, Ciliberto G, Savino R: Definition of a composite binding site for gp130 in human interleukin-6 (IL-6). J Biol Chem 270:31249, 1995
34. Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155:335, 1987
35. Toniatti C, Cabibbo A, Sporeno E, Salvati AL, Cerretani M, Serafini S, Lahm A, Cortese R, Ciliberto G: Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO J (in press)
36. Fiorillo MT, Cabibbo A, Iacopetti P, Fattori E, Ciliberto G: Analysis of human/mouse IL-6 hybrid proteins: only amino- and carboxy-termini of human IL-6 are required for species-specific receptor binding. Eur J Immunol 22:2609, 1992
37. Studier FW, Moffatt BA: Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113, 1986
38. Sanger F, Nickeln S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463, 1977
39. Arcone R, Pucci P, Zappacosta F, Fontaine V, Malorni A, Marino G, Ciliberto G: Single step purification and structural characterization of human interleukin-6 produce in E. coli from a T7 RNA polymerase expression vector. Eur J Biochem 198:541, 1991
40. Cabibbo A, Sporeno E, Toniatti C, Altamura S, Savino R, Paonessa G, Ciliberto G: Monovalent phage display of human in-terleukin (hIL)-6: Selection superbinder variants for a complex molecular repertoire in hIL-6 D-Helix. Gene 167:41, 1995
41. Gregory B, Savino R, Ciliberto G: A fast and sensitive colorimetric assay for IL-6 on hepatoma cells based on the production of a secreted form of alkaline phosphatase (SEAP). J Immunol Methods 170:47, 1994
42. Horn D, Fitzpatrick WC, Gompper PT, Ochs PT, Bolton-Hansen M, Zarling JM, Malik N, Todaro GJ, Linsley PS: Regulation of cell growth by recombinant oncostatin M. Growth Factors 2:157, 1990
43. Zhang X-G, Gaillard J-P, Robillard N, Lu Z-Y, Gu Z-J, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stemm cell study in human MM. Blood 83:3654, 1994
44. Carson M: Ribbon models of macromolecules. J Mol Graphics 5:103, 1987
45. Savino R, Lahm A, Giorgio M, Cabibbo A, Tramontano A, Ciliberto G: Saturation mutagenesis of the human interleukin 6 receptor binding site implications for its three-dimensional structure. Proc Natl Acad Sci USA 90:4067, 1993
46. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B: IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 147:4402, 1991
47. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G: Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773, 1989
48. Bruce AG, Hoggatt IH, Rose TM: Oncostatin M is a differentiation factor for myeloid leukemia cells. J Immunol 149:1271, 1992
49. Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, K, Shoyab M, Taga T, Kishimoto T, Bataille R, Klein B: Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 179:1337, 1994b
50. Levy Y, Tsapis A, Briuet JC: Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991
51. Brakenhoff JPJ, Hart M, de Groot ER, Di Padova F, Aarden LA: Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol 145:561, 1990
52. Klein B: Cytokine, cytokine receptors, transduction signals, and receptor in human multiple myeloma. Semin Hematol 32:4, 1995
53. Rodriguez C, Theillet C, Portier: Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease. FEBS Lett 341:156, 1994
54. Kawano MM, Miliara K, Huang N, Tsujimoto T, Kuramoto A: Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85:487, 1995
55. Hardin J, Macleod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cells death. Blood 84:3063, 1994
56. L. Cancer Res 55:2262, 1995
57. l and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 6:647, 1995
58. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K-I, Ohsugi Y, Yoshida O: Cancer research. Sensitization of human renal cell carcinoma cells to cis-diamminedi-chloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6 monoclonal antibody or anti-interleukin-6 receptor monoclonal antibody. Cancer Res 55:590, 1995